Kintor Pharma Announced the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Female Androgenetic Alopecia in China Was Met : vimarsana.com

Kintor Pharma Announced the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Female Androgenetic Alopecia in China Was Met

DJ Kintor Pharma Announced the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Female Androgenetic Alopecia in China Was Met EQS Newswire / 02/12/2022 / 10:34 UTC+8 Kintor

Related Keywords

China , Peking , Beijing , Suzhou , Jiangsu , Kintor Pharma , Jianzhong Zhang , Financial Press , Kintor Pharmaceutical , Department Of Dermatology , University People Hospital , Kintor Pharmaceutical Limited Pharma , Pharma Announced , Primary Endpoint , Female Androgenetic Alopecia , China Was Met , Pharmaceutical Limited , Peking University People , Savin Scale , Youzhi Tong , Chief Executive Officer , Kintor Pharma Announced , Financial Press Release , Dow Jones Newswires , Ukintor , Harma , Nnounced , Rimary , Ndpoint , Hase , Linical , Tudy , Reatment , Emale , Androgenetic , Lopecia ,